X-ray technology developer Lumitron Technologies has unveiled HyperView, a new laser-based imaging platform that the company believes offers the potential for finding and treating disease at the cellular level.
Utilizing a proprietary x-ray technology developed at the Lawrence Livermore National Laboratory (LLNL), HyperView is based on the 2018 Nobel Prize-winning achievement in physics that enables the creation of high-energy, short-duration laser pulses, according to Lumitron. It can produce single-color x-rays that can lead to both cellular-level identification and treatment of disease, the company said.
The platform is the result of three previous complete generations of machine design, construction, and testing at LLNL and more than $220 million of R&D investments in advanced x-ray, laser, and accelerator science by the U.S. Department of Energy, Lumitron said.
The company's global R&D and manufacturing facility has now been established within the industrial park at the University of California, Irvine (UCI). Chris Barty of UCI and former chief technology officer of LLNL's National Ignition Facility and Photon Science has overseen the establishment of Lumitron's commercial endeavor in Irvine, and he is now shepherding the company's development of the patents he helped create, Lumitron said. Lumitron holds exclusive commercial rights to the HyperView technology.
